The real world study of tislilizumab in the treatment of locally advanced or metastatic urothelial carcinoma

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000033177

Enrollment

Unknown

Registered

2020-05-23

Start date

2020-07-01

Completion date

Unknown

Last updated

2020-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urothelial carcinoma

Interventions

immunotherapy group:Tislelizumab, IV, 200mg, Q3w

Eligibility

Sex/Gender

All

Age

45 Years to 90 Years

Inclusion criteria

Inclusion criteria: In patients with locally advanced or metastatic urothelial carcinoma who have progressed within 12 months, the failure of platinum containing chemotherapy includes neoadjuvant or adjuvant chemotherapy.

Exclusion criteria

Exclusion criteria: Poor general health, investigators assess patients who are not suitable for immunotherapy.

Design outcomes

Primary

Measure	Time frame
ORR;	—

Secondary

Measure	Time frame
DCR;PFS;DOR;	—

Countries

China

Contacts

Public ContactGou Xin

The First Affiliated Hospital of Chongqing Medical University

gouxincq@163.com+86 13883369433

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026